AIM ImmunoTech Inc. converted approximately $400,000 of its outstanding Promissory Note into 1,749,434 shares of common stock at an average conversion price of $0.228 per share through exchange agreements with Streeterville Capital, LLC. This transaction was approved by stockholders at a special meeting on July 15, 2026, and executed between September 8 and 9, 2026. The company operates in the biotechnology industry, focusing on immunotherapy treatments.

AIM ImmunoTech Inc. entered into exchange agreements with Streeterville Capital, LLC to convert approximately $450,000 of outstanding debt under a November 2025 promissory note into 1,921,441 shares of common stock at an average conversion price of $0.234 per share. This transaction was approved by stockholders at a special meeting on July 15, 2026. The company operates in the biotechnology industry, focusing on immunotherapy treatments.

AIM ImmunoTech Inc. converted approximately $1,224,341 of outstanding debt under a Promissory Note dated February 16, 2024 into 5,065,840 shares of common stock at an average conversion price of $0.24 per share. The transaction was executed through five exchange agreements and partitioned promissory notes with Streeterville Capital, LLC between August 31 and September 3, 2026. This equity issuance satisfied the Promissory Note in full, eliminating all amounts owed under that instrument following prior stockholder approval at a special meeting on July 15, 2026. AIM ImmunoTech Inc. operates in the biotechnology industry, focusing on immunotherapy and vaccine development.

AIM ImmunoTech Inc. received a letter from NYSE Regulation on June 12, 2026, confirming the company has regained compliance with all NYSE American LLC continued listing standards, specifically resolving deficiencies under Section 1003(a)(i), (ii), and (iii). The company's trading symbol will no longer carry the "below compliance" indicator. AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-based therapies.

AIM ImmunoTech Inc. entered into a securities purchase agreement on June 9, 2026, to conduct a registered direct offering of 2,554,119 shares of common stock at $0.5189 per share, expected to raise approximately $1.3 million. The company also conducted a concurrent private placement of 771,503 shares, pre-funded warrants, and Class J warrants, which could potentially provide an additional $5.3 million in gross proceeds. AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-based therapies.

On June 9, 2026, AIM ImmunoTech Inc. Board of Directors approved and adopted an Amendment to the Company's Amended and Restated Bylaws, changing the voting standard for proposals other than director elections to a majority of the votes cast on the proposal. AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-oncology therapies.